Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.22 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.22 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the difficulties faced in the quarter. They emphasized their commitment to future projects and maintaining operational focus.
Management did not provide specific revenue figures for the quarter.
The company remains focused on its long-term goals despite current challenges.
The earnings report reflects ongoing challenges for Soleno Therapeutics, particularly with their EPS figures. The lack of revenue data and guidance may raise concerns among investors. The stock's decline of 1.62% indicates a cautious market reaction to the uncertainties presented in the call.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
RIOT PLATFORMS INC
May 10, 2019